The effects of both noradrenaline and CGP12177, mediated through human β1-adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 375, Issue 2, 2007, Pages 123-131

  Kaumann, Alberto ^a   Semmler, Annalese B T ^b   Molenaar, Peter ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

1 adrenoceptor sites; ( ) CGP12177; ( ) noradrenaline; CHO cell cAMP; Human atrium; Phosphodiesterase isoenzymes

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; BETA 1 ADRENERGIC RECEPTOR; CILOSTAMIDE; CYCLIC AMP; NORADRENALIN; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ADULT; AGED; ANALYTIC METHOD; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART ATRIUM; HEART MUSCLE; HEART VENTRICLE; HUMAN; INOTROPISM; MALE; NONHUMAN; RAT; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-AGONISTS; AGED; ANIMALS; ATRIAL APPENDAGE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DRUG SYNERGISM; FEMALE; HUMANS; ISOMETRIC CONTRACTION; ISOPROTERENOL; MALE; MIDDLE AGED; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PROPANOLAMINES; QUINOLONES; RECEPTORS, ADRENERGIC, BETA-1; ROLIPRAM; SIGNAL TRANSDUCTION;

EID: 33947272024     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0140-3     Document Type: Article

References (32)

1. 1-adrenoceptors in human myocardium. J Pharmacol Exp Ther 300:794-801
2. Christ T, Molenaar P, Galindo-Tovar A, Ravens U, Kaumann AJ (2006a) Contractile responses through Gs-coupled receptors are reduced by phosphodiesterase3 activity in human isolated myocardium. Biochemical Society focusing meeting. Compartmentalization of cyclic AMP signalling. King's College, Cambridge, UK, pp 29-30 March, P014
3. 1-adrenoceptors in human atrial myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 374:249-253
4. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C (2005) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis. Implications in heart failure. Circulation 111:2469-2476
5. Gille E, Lemoine H, Ehle B, Kaumann AJ (1985) The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn-Schmiedeberg's Arch Pharmacol 331:60-70
6. Gossen M, Buhard H (1992) Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc Natl Acad Sci USA 89:5547-5551
7. 2-adrenoceptors in human atrial myocardium. Circ Res 66:1610-1623
8. Houslay MLM, Schafer P, Zhang KYZ (2005) Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519
9. 1-adrenoceptor in human atrium and recombinant receptors. Naunyn-Schmiedeberg's Arch Pharmacol 368:496-503
10. 1-adrenoceptors and interactions with β-blockers. Naunyn-Schmiedeberg's Arch Pharmacol 369:525-532
11. Katano Y, Endoh M (1992) Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. J Cardiovasc Pharmacol 20:715-722
12. Kaumann AJ (1973) Adrenergic receptors in heart muscle. Two different mechanisms of ?-blockers as partial agonists. International union of biochemistry, symposium 52. Acta Physiol Lat Am 23:235-236
13. Kaumann AJ (1996) (-)-CGP12177-induced increase of human atrial contraction through a putative third β-adrenoceptor. Br J Pharmacol 117:93-98
14. s protein-coupled receptors in human heart. In: Kenakin T, Angus JA (eds) The pharmacology of functional, biochemistry, and recombinant receptor systems. Handbook of experimental pharmacology, vol 148. Springer, Berlin, pp 73-116
15. Kaumann AJ, Lemoine H (1987) Beta2-adrenoceptor-mediated positive inotropic effects of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn-Schmiedeberg's Arch Pharmacol 331:60-70
16. Kaumann AJ, Lynham JA (1997) Stimulation of cyclic AMP-dependent protein kinase in rat atria by (-)-CGP12177 through an atypical β-adrenoceptor. Br J Pharmacol 129:1187-1189
17. 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J 10(Suppl B):29-37
18. Lugnier C, Muller B, Lebec A, Beaudry C, Rousseau E (1993) Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 265:1142-1151
19. 1- adrenergic receptor. J Biol Chem 274:12670-12674
20. 3-adrenoceptors. Br J Pharmacol 120:165-176
21. Molenaar P, Rabnott G, Yang I, Fong KM, Savarimuthu SM, Li L, West MJ, Russell FD (2002) Conservation of the cardiostimulant effects of (-)-norepinephrine across Ser49gly and Gly389arg beta1-adrenergic receptor polymorphisms in human right atrium in vitro. J Am Coll Cardiol 40:1275-1282
22. 2-adrenoceptors in human atrial myocardium from non-failing and failing hearts, consistent with Gs coupling but not with Gi coupling. Naunyn-Schmiedeberg's Arch Pharmacol DOI 10.1007/s00210-007-0138-x
23. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse M, Pozzan T, Houslay MD, Zaccolo M (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75
24. Nicholson CD, Challiss RA, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19-27
25. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med 325:1468-1475
26. 2-adrenergic receptors by β-arrestin. Science 298:834-836
27. 4- adrenoceptor in rat atrium. Br J Pharmacol 123:371-380
28. 3H]-CGP12177 binding. Br J Pharmacol 128:1445-1460
29. Sarsero D, Russell FD, Rabnott G, Yang I, Fong KM, Li L, Kaumann AJ, Molenaar P (2003) (-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the β-adrenoceptor. Naunyn-Schmiedeberg's Arch Pharmacol 367:10-21
30. Schmitz W, Eschenhagen T, Mende U, Muller FU, Neumann J, Scholz H (1992) Phosphodiesterase inhibition and positive inotropy in failing human myocardium. Basic Res Cardiol 87(Suppl 1):65-71
31. Shakur J, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y (2002) Comparisons of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 16:417-427
32. Vargas ML, Hernandez-Cascales J, Kaumann AJ (2006) Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle. Br J Pharmacol 147:158-163